Sotera Health (NASDAQ:SHC) Releases FY24 Earnings Guidance

Sotera Health (NASDAQ:SHC - Get Free Report) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $0.67 to $0.75 for the period, compared to the consensus EPS estimate of $0.71. The company issued revenue guidance of +4 to +6% yr/yr or $1.091 billion to $1.112 billion, compared to the consensus revenue estimate of $1.10 billion.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. KeyCorp assumed coverage on Sotera Health in a research report on Tuesday, February 6th. They set a sector weight rating on the stock. Jefferies Financial Group upgraded Sotera Health from a hold rating to a buy rating and boosted their price objective for the company from $15.00 to $15.50 in a report on Monday, March 25th. Barclays dropped their price objective on Sotera Health from $19.00 to $14.00 and set an overweight rating for the company in a report on Wednesday, April 10th. TheStreet upgraded Sotera Health from a d rating to a c- rating in a report on Tuesday, February 27th. Finally, Citigroup upgraded Sotera Health from a neutral rating to a buy rating and dropped their price objective for the company from $18.00 to $16.00 in a report on Wednesday, April 3rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $17.70.

Sotera Health Stock Down 3.2 %

Shares of SHC traded down $0.36 during midday trading on Thursday, reaching $10.91. 1,637,483 shares of the stock were exchanged, compared to its average volume of 1,553,887. Sotera Health has a 52 week low of $10.71 and a 52 week high of $19.40. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 5.16. The company's 50 day moving average is $12.68 and its two-hundred day moving average is $14.05. The company has a market capitalization of $3.09 billion, a P/E ratio of 60.44 and a beta of 2.08.

Sotera Health (NASDAQ:SHC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Sotera Health had a return on equity of 51.32% and a net margin of 4.90%. The business had revenue of $310.24 million for the quarter, compared to the consensus estimate of $302.17 million. During the same quarter in the prior year, the company earned $0.23 EPS. The business's revenue was up 23.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Sotera Health will post 0.64 earnings per share for the current year.

Insider Transactions at Sotera Health

In other Sotera Health news, Director Pincus & Co. Warburg sold 16,594,363 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $237,465,334.53. Following the completion of the sale, the director now directly owns 88,822,952 shares in the company, valued at $1,271,056,443.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Michael P. Rutz sold 83,109 shares of the firm's stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $1,189,289.79. Following the completion of the transaction, the insider now directly owns 544,409 shares in the company, valued at $7,790,492.79. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Pincus & Co. Warburg sold 16,594,363 shares of the firm's stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $237,465,334.53. Following the completion of the transaction, the director now owns 88,822,952 shares of the company's stock, valued at $1,271,056,443.12. The disclosure for this sale can be found here. Corporate insiders own 55.12% of the company's stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.